A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission
Status:
Recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
Participants who are in clinical remission on 200 mg filgotinib once daily (q.d.) for at
least 2 consecutive quarterly visits in the ongoing SELECTION-LTE study (GS-US-418-3899,
NCT02914535), are planned to be rolled over and randomized in this study. The primary
objective of this study is to evaluate the efficacy of filgotinib in participants in stable
clinical remission on 200 mg filgotinib q.d. for whom the dose was decreased to 100 mg q.d.
compared to participants remaining on 200 mg q.d.